Trial Profile
Brilinta Tablets 60mg/90mg Clinical Experience Investigation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Acute coronary syndromes; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRLCEIACS/OMI
- Sponsors AstraZeneca
- 01 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2020 Planned End Date changed from 28 Jun 2024 to 30 Mar 2028.
- 16 Jun 2020 Planned primary completion date changed from 28 Jun 2024 to 30 Mar 2028.